Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06212999




Registration number
NCT06212999
Ethics application status
Date submitted
9/01/2024
Date registered
19/01/2024
Date last updated
25/11/2024

Titles & IDs
Public title
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Scientific title
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Secondary ID [1] 0 0
2023-507204-31-00
Secondary ID [2] 0 0
INCB 54707-312
Universal Trial Number (UTN)
Trial acronym
STOP-HS LTE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hidradenitis Suppurativa (HS) 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Povorcitinib

Experimental: Cohort A - Povorcitinib at the protocol-defined dose strength based on cohort assignment.

Experimental: Cohort B - Povorcitinib at the protocol-defined dose strength based on cohort assignment.

Experimental: Cohort C - Povorcitinib at the protocol-defined dose strength based on cohort assignment.


Treatment: Drugs: Povorcitinib
Oral; Tablet
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)
Timepoint [1] 0 0
up to approximately 56 weeks
Secondary outcome [1] 0 0
Proportion of participants with Serious Treatment-Emergent Adverse Events (TEAEs)
Timepoint [1] 0 0
up to approximately 56 weeks
Secondary outcome [2] 0 0
Proportion of participants with TEAEs leading to study drug discontinuation
Timepoint [2] 0 0
up to approximately 56 weeks
Secondary outcome [3] 0 0
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)
Timepoint [3] 0 0
up to approximately 56 weeks
Secondary outcome [4] 0 0
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)
Timepoint [4] 0 0
up to approximately 56 weeks
Secondary outcome [5] 0 0
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 90 (HiSCR90)
Timepoint [5] 0 0
up to approximately 56 weeks
Secondary outcome [6] 0 0
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 100 (HiSCR100)
Timepoint [6] 0 0
up to approximately 56 weeks
Secondary outcome [7] 0 0
Proportion of participants with flare at each visit
Timepoint [7] 0 0
up to approximately 56 weeks
Secondary outcome [8] 0 0
Time to first flare
Timepoint [8] 0 0
up to approximately 56 weeks
Secondary outcome [9] 0 0
Mean change from baseline of parent study in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each visit
Timepoint [9] 0 0
up to approximately 56 weeks
Secondary outcome [10] 0 0
Mean change from baseline of parent study in Dermatology Life Quality Index (DLQI) score at each visit
Timepoint [10] 0 0
up to approximately 56 weeks
Secondary outcome [11] 0 0
Proportion of participants with no increase in abscess and inflammatory nodule (AN) count relative to Week 54 at each visit
Timepoint [11] 0 0
up to approximately 56 weeks
Secondary outcome [12] 0 0
Proportion of participants with no increase in abscess, inflammatory nodule, and draining tunnel (ANdT) count relative to Week 54 at each visit
Timepoint [12] 0 0
up to approximately 56 weeks
Secondary outcome [13] 0 0
Proportion of participants with no increase in draining tunnel count relative to Week 54 at each visit
Timepoint [13] 0 0
up to approximately 56 weeks
Secondary outcome [14] 0 0
Proportion of participants with a total AN count of 0, 1, or 2 at each visit
Timepoint [14] 0 0
up to approximately 56 weeks
Secondary outcome [15] 0 0
Proportion of participants with a total ANdT count of 0, 1, or 2 at each visit
Timepoint [15] 0 0
up to approximately 56 weeks

Eligibility
Key inclusion criteria
* Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).
* Agreement to use contraception.
* Willing and able to comply with the study protocol and procedures.
* Further inclusion criteria apply.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participation in the extension study could expose the participant to an undue safety risk.
* Women who are pregnant (or who are considering pregnancy) or breastfeeding.
* Further exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/01/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
26/12/2026
Actual
Sample size
Target
960
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Investigative Site AU205 - Kogarah
Recruitment hospital [2] 0 0
Investigative Site AU203 - Kotara
Recruitment hospital [3] 0 0
Investigator Site AU200 - Liverpool
Recruitment hospital [4] 0 0
Investigative Site AU206 - Woolloongabba
Recruitment hospital [5] 0 0
Investigative Site AU207 - Woolloongabba
Recruitment hospital [6] 0 0
Investigator Site AU201 - Carlton
Recruitment hospital [7] 0 0
Investigative Site AU204 - Melbourne
Recruitment postcode(s) [1] 0 0
02217 - Kogarah
Recruitment postcode(s) [2] 0 0
02289 - Kotara
Recruitment postcode(s) [3] 0 0
02170 - Liverpool
Recruitment postcode(s) [4] 0 0
04102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
03053 - Carlton
Recruitment postcode(s) [6] 0 0
03002 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
New Hampshire
Country [18] 0 0
United States of America
State/province [18] 0 0
New Jersey
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Austria
State/province [27] 0 0
Innsbruck
Country [28] 0 0
Austria
State/province [28] 0 0
Vienna
Country [29] 0 0
Belgium
State/province [29] 0 0
Brussels
Country [30] 0 0
Belgium
State/province [30] 0 0
Gent
Country [31] 0 0
Belgium
State/province [31] 0 0
Ghent
Country [32] 0 0
Belgium
State/province [32] 0 0
Liege
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Sofia
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Stara Zagora
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
British Columbia
Country [37] 0 0
Canada
State/province [37] 0 0
Manitoba
Country [38] 0 0
Canada
State/province [38] 0 0
New Brunswick
Country [39] 0 0
Canada
State/province [39] 0 0
Ontario
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec
Country [41] 0 0
Canada
State/province [41] 0 0
St. John's
Country [42] 0 0
Czechia
State/province [42] 0 0
Ostrava - Poruba
Country [43] 0 0
Czechia
State/province [43] 0 0
Praha 5
Country [44] 0 0
Denmark
State/province [44] 0 0
Aarhus
Country [45] 0 0
Denmark
State/province [45] 0 0
Roskilde
Country [46] 0 0
France
State/province [46] 0 0
Bordeaux
Country [47] 0 0
France
State/province [47] 0 0
Brest Cedex 2
Country [48] 0 0
France
State/province [48] 0 0
Dijon
Country [49] 0 0
France
State/province [49] 0 0
Le Mans Cedex 9
Country [50] 0 0
France
State/province [50] 0 0
Lyon
Country [51] 0 0
France
State/province [51] 0 0
Marseille Cedex 5
Country [52] 0 0
France
State/province [52] 0 0
Nantes
Country [53] 0 0
France
State/province [53] 0 0
Nice Cedex 3
Country [54] 0 0
France
State/province [54] 0 0
Paris
Country [55] 0 0
France
State/province [55] 0 0
Reims
Country [56] 0 0
France
State/province [56] 0 0
Rouen Cedex
Country [57] 0 0
France
State/province [57] 0 0
Saint Etienne Cedex 2
Country [58] 0 0
France
State/province [58] 0 0
Toulouse Cedex 9
Country [59] 0 0
Germany
State/province [59] 0 0
Berlin
Country [60] 0 0
Germany
State/province [60] 0 0
Bochum
Country [61] 0 0
Germany
State/province [61] 0 0
Darmstadt
Country [62] 0 0
Germany
State/province [62] 0 0
Dessau
Country [63] 0 0
Germany
State/province [63] 0 0
Dresden
Country [64] 0 0
Germany
State/province [64] 0 0
Duesseldorf
Country [65] 0 0
Germany
State/province [65] 0 0
Erlangen
Country [66] 0 0
Germany
State/province [66] 0 0
Frankfurt
Country [67] 0 0
Germany
State/province [67] 0 0
Gottingen
Country [68] 0 0
Germany
State/province [68] 0 0
Hamburg
Country [69] 0 0
Germany
State/province [69] 0 0
Hannover
Country [70] 0 0
Germany
State/province [70] 0 0
Kiel
Country [71] 0 0
Germany
State/province [71] 0 0
Leipzig
Country [72] 0 0
Germany
State/province [72] 0 0
Lubeck
Country [73] 0 0
Germany
State/province [73] 0 0
Memmingen
Country [74] 0 0
Germany
State/province [74] 0 0
Merzig
Country [75] 0 0
Greece
State/province [75] 0 0
Athens
Country [76] 0 0
Greece
State/province [76] 0 0
Thessaloniki
Country [77] 0 0
Italy
State/province [77] 0 0
Ancona
Country [78] 0 0
Italy
State/province [78] 0 0
Catania
Country [79] 0 0
Italy
State/province [79] 0 0
Milano
Country [80] 0 0
Italy
State/province [80] 0 0
Napoli
Country [81] 0 0
Italy
State/province [81] 0 0
Pisa
Country [82] 0 0
Italy
State/province [82] 0 0
Roma
Country [83] 0 0
Italy
State/province [83] 0 0
Rozzano
Country [84] 0 0
Japan
State/province [84] 0 0
Itabashi-ku
Country [85] 0 0
Japan
State/province [85] 0 0
Kurume
Country [86] 0 0
Japan
State/province [86] 0 0
Kyoto-shi
Country [87] 0 0
Japan
State/province [87] 0 0
Nakagami-gun
Country [88] 0 0
Japan
State/province [88] 0 0
Niigata-shi
Country [89] 0 0
Japan
State/province [89] 0 0
Sapporo-shi
Country [90] 0 0
Japan
State/province [90] 0 0
Sendai-shi
Country [91] 0 0
Japan
State/province [91] 0 0
Shinjuku-ku
Country [92] 0 0
Netherlands
State/province [92] 0 0
Breda
Country [93] 0 0
Netherlands
State/province [93] 0 0
Groningen
Country [94] 0 0
Netherlands
State/province [94] 0 0
Rotterdam
Country [95] 0 0
Poland
State/province [95] 0 0
Lublin
Country [96] 0 0
Poland
State/province [96] 0 0
Ostrowiec
Country [97] 0 0
Poland
State/province [97] 0 0
Rzeszow
Country [98] 0 0
Poland
State/province [98] 0 0
Warszawa
Country [99] 0 0
Poland
State/province [99] 0 0
Wroclaw
Country [100] 0 0
Spain
State/province [100] 0 0
Alicante
Country [101] 0 0
Spain
State/province [101] 0 0
Badalona
Country [102] 0 0
Spain
State/province [102] 0 0
Barcelona
Country [103] 0 0
Spain
State/province [103] 0 0
Granada
Country [104] 0 0
Spain
State/province [104] 0 0
Las Palmas de Gran Canaria
Country [105] 0 0
Spain
State/province [105] 0 0
Madrid
Country [106] 0 0
Spain
State/province [106] 0 0
Manises
Country [107] 0 0
Spain
State/province [107] 0 0
Pontevedra
Country [108] 0 0
Spain
State/province [108] 0 0
Santiago de Compostela
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Birmingham
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Dudley
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Leeds
Country [112] 0 0
United Kingdom
State/province [112] 0 0
London
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Incyte Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Trial website
https://clinicaltrials.gov/study/NCT06212999
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Incyte Medical Monitor
Address 0 0
Incyte Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Incyte Corporation Call Center (US)
Address 0 0
Country 0 0
Phone 0 0
1.855.463.3463
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06212999